口服复方激素避孕药在多囊卵巢综合征中的非避孕用途——风险与获益
本文综述口服复方激素避孕药在多囊卵巢综合征(PCOS)中用于治疗月经不规律、痤疮和多毛的获益与风险。现有研究多未提示口服避孕药增加糖尿病前期/糖尿病、临床显著血脂异常、炎症变化或抑郁/焦虑症状风险,但缺乏评估不同炔雌醇剂量、孕激素类型及肥胖等混杂因素的大规模长期研究。建议筛查心血管代谢及精神共病并个体化用药。
要点
- 口服复方激素避孕药是PCOS月经不规律、痤疮和多毛的一线治疗。
- 多数现有研究未提示口服避孕药增加糖尿病前期/糖尿病、血脂异常或抑郁/焦虑风险。
- 缺乏评估不同炔雌醇剂量和孕激素类型的大规模长期研究。
核心结论
- 现有研究多未提示PCOS女性使用口服避孕药增加糖尿病前期/糖尿病、临床显著血脂异常、炎症变化或抑郁/焦虑症状的风险。
- 缺乏评估不同炔雌醇剂量、孕激素类型及肥胖、吸烟等混杂因素的大规模研究,是相关讨论的重要局限。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 多数现有研究未提示口服避孕药使用与糖尿病前期/糖尿病、临床显著血脂异常、炎症变化或抑郁/焦虑症状风险增加相关。
- 关于PCOS女性心血管事件等主要疾病的长期数据匮乏。
临床怎么用
- 多个医学学会已认可使用性激素获得非避孕获益。
- 常规推荐筛查PCOS女性的心血管代谢及精神共病。
- 医疗提供者应据此个体化选择激素避孕治疗、充分告知风险与获益并制定合适的随访计划。
局限性
- 缺乏评估不同炔雌醇剂量、孕激素类型及肥胖、吸烟和其他心血管代谢共病等混杂因素风险的大规模研究。
- 目前关于PCOS女性心血管事件等主要疾病的长期数据匮乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of steroid sex hormones for noncontraceptive benefits has been endorsed by several medical societies. In women with polycystic ovary syndrome (PCOS), hormonal contraceptives are first-line therapy for concurrent treatment of menstrual irregularity, acne, and hirsutism. The association of PCOS with obesity, diabetes, and dyslipidemia frequently brings up the debate regarding risks versus benefits of hormonal contraceptives in this population. In women with PCOS, the lack of large-scale studies evaluating the risks with varying doses of ethinyl estradiol, types of progestins, and presence of confounding factors such as obesity, smoking, and other cardiometabolic comorbidities is a significant limitation in these deliberations. Although it is important to assess the absolute risk for major morbidities including cardiovascular events, currently, there are a paucity of long-term data for these outcomes in PCOS. Most of the current studies do not suggest an increase in risk of prediabetes/diabetes, clinically significant dyslipidemia, inflammatory changes, or depressive/anxiety symptoms with oral contraceptive pill use. Screening of women with PCOS for cardiometabolic and psychiatric comorbidities is routinely recommended. This information should be used by health care providers to individualize the choice of hormonal contraceptive treatment, adequately counsel patients regarding risks and benefits, and formulate an appropriate follow-up plan.
引用
- Dokras A. Noncontraceptive use of oral combined hormonal contraceptives in polycystic ovary syndrome-risks versus benefits. Fertil Steril. 2016. PMID: 27817838. doi:10.1016/j.fertnstert.2016.10.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。